Investigator Detail in Open Payments
With Open Payments US investigator names and experience will become public knowledge.
ClinicalTrials.gov has become a widely used operational and research tool. ClinicalTrials.gov has now reached the credibility level that almost all major medical journals require clinical trials discussed in that specific journal be available in ClinicalTrials.gov. The level of missing data for these mandatory variables, with one major exception, rarely exceed 2-3%. This exception is investigator detail. Not all sites are included or updated in ClinicalTrials.gov. Moreover, the data are rarely complete for the sites which are entered. For the sites in ClinicalTrials.gov, the country is almost always given. For US sites, the relevant zip code is frequently given. Usually no other information is given, although the database does require that the name and address of the investigator be indicated.
Open Payments helps fill this information gap for US sites. Open Payments, mandated by the Sunshine Act, contains all the payments by pharmaceutical and medical devices manufacturers to certain healthcare professionals, including physicians. The payments are of two types, research payments and all other general transfers of value. With the research payments, it is possible to identify the specific clinical trial for which the respective research payments were made to the clinical investigators.
A Sanofi study illustrates the data available from Open Payments. Sanofi conducted a phase 3 study between 2013 and 2014 with US sites, with a study title:
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients with Rheumatoid Arthritis.
Sanofi provided a listing of sites with zip codes to ClinicalTrials.gov, but no other public investigator identification information. Open Payments provided that detail for each investigator and identified three more physicians not listed in CT.gov. From Open Payments for each investigator we have the institutional or practice name, the physician’s name, exact address and specialty. The Sanofi detail can be replicated for a near census of US clinical trials. With Open Payments US investigator names and experience will become public knowledge.
Investigator Detail
Study NCT02121210
Physician
Address
City
State
Zip
JAIME PACHON
6141 SUNSET DR
SOUTH MIAMI
FL
33143-5028
DAKSHA MEHTA
584 WESTPORT RD
ELIZABETHTOWN
KY
42701-2987
ERDAL DIRI
400 BURDICK EXPY E
MINOT
ND
58701-4768
MOHAMMAD KHAN
1110 N LEE
OKLAHOMA CITY
OK
73103
ELLEN ZANETAKIS
1430 TERRACE DR
TULSA
OK
74104-4626
ALAN KIVITZ
175 MEADOWBROOK LN
DUNCANSVILLE
PA
16635-8445
Jacob Aelion
371 N PARKWAY
JACKSON
TN
38305-2891
CONSTANTINE SAADEH
6842 PLUM CREEK DR
AMARILLO
TX
79124-1601
ATUL SINGHAL
1600 REPUBLIC PARKWAY
MESQUITE
TX
75150-6919
SHELLY KAFKA
399 EMILY DR
CLARKSBURG
WV
26301-5505
Alvin Wells
4225 W OAKWOOD PARK COURT
FRANKLIN
WI
53132
MICHAEL FAIRFAX
2451 E BASELINE RD
GILBERT
AZ
85234-2471
Eric Lee
1238 E ARROW HWY
UPLAND
CA
91786-4951
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
